Illumina licenses Orchid Cellmark DNA technology

Xconomy San Diego — 

San Diego’s Illumina (NASDAQ: [[ticker: ILMN]]) has licensed worldwide rights to commercially develop Orchid Cellmark’s proprietary single base nucleotide extension technology for forensics and diagnostics. Princeton, N.J.-based Orchid (NASDAQ: ORCH) is one of the largest providers of forensic DNA testing services used by the criminal justice system. Orchid says Illumina agreed to pay $850,000 upfront and up to $150,000 in milestone payments. Although Orchid retains the right to use its patents, Illumina received exclusive rights to sublicense the technology. Orchid will receive royalties on any such deals.

By posting a comment, you agree to our terms and conditions.

2 responses to “Illumina licenses Orchid Cellmark DNA technology”

  1. santabarbara1 says:

    Triboro Fibers receives and separates the recyclable paper into various grades, which is then sold in the open market with the majority of the paper being sold as export .Please visited my website Paper Processing .